Comparative review of imipenem/cilastatin versus meropenem.
Anti-Bacterial Agents
/ adverse effects
Bacterial Infections
/ drug therapy
Biotransformation
Child
Child, Preschool
Cilastatin, Imipenem Drug Combination
/ adverse effects
Contraindications, Drug
Drug Resistance, Microbial
Drug Resistance, Multiple, Bacterial
Drug Stability
Female
Gram-Negative Bacteria
/ drug effects
Gram-Positive Bacteria
/ drug effects
Humans
Infant
Liver Failure
/ metabolism
Meropenem
/ adverse effects
Molecular Structure
Organ Specificity
Pregnancy
Pregnancy Complications, Infectious
/ drug therapy
Protein Binding
Antibiotic stewardship
Carbapenem
Imipenem/cilastatin
Meropenem
Journal
Medecine et maladies infectieuses
ISSN: 1769-6690
Titre abrégé: Med Mal Infect
Pays: France
ID NLM: 0311416
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
25
11
2018
revised:
17
03
2019
accepted:
10
01
2020
pubmed:
10
2
2020
medline:
25
8
2021
entrez:
10
2
2020
Statut:
ppublish
Résumé
Carbapenems are broad-spectrum antibacterial molecules. Imipenem-cilastatin and meropenem are the two main molecules used in French healthcare services. We aimed to evaluate the relative strengths and weaknesses of these two molecules by considering their pharmacokinetic, pharmacodynamic, microbiological, and clinical properties. We demonstrated that imipenem-cilastatin and meropenem are not alike. Review of the literature by querying the MEDLINE network. Imipenem-cilastatin is the first marketed molecule of the carbapenem class. It is more effective against Gram-positive cocci. Its stability does not allow for long infusions and its main adverse effect on the central nervous system limits its use. Meropenem is more effective against Gram-negative bacilli. Its stability and its milder adverse effects distinguish it from imipenem-cilastatin. Meropenem is preferred for daily use in healthcare services when carbapenems are to be used.
Identifiants
pubmed: 32035719
pii: S0399-077X(20)30025-1
doi: 10.1016/j.medmal.2020.01.001
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cilastatin, Imipenem Drug Combination
92309-29-0
Meropenem
FV9J3JU8B1
Types de publication
Comparative Study
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
316-322Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.